Regulation of Lipoprotein Transport in Metabolic Syndrome

The University of Western Australia13 enrolled

Overview

The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.

The metabolic syndrome (MetS) portends diabetes and cardiovascular disease (CVD). Dyslipoproteinaemia, reflected by elevated plasma triglyceride and reduced high-density lipoprotein (HDL) concentrations, is a cardinal feature of MetS that independently predicts CVD and is accordingly a therapeutic target for risk reduction. GW5015156 is a new PPAR-delta agonist that could be used to treat dyslipidemia in insulin resistance and obesity. However, the precise mechanisms of action of this agent on lipoprotein kinetics in MetS subjects have not yet fully been investigated. We therefore carried out a study to study the effect of GW5015156 on lipoprotein transport in subject with metabolic syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Obesity Lipid Disorders Cardiovascular Disease

Interventions

GW501516DRUG

2.5mg/day

placebo pillDRUG

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any three of the following: * Waist circumference \> 102 cm * Triglycerides \> 150 mg/dL * HDL-cholesterol \< 40 mg/dL * Blood glucose \> 110 mhg/dL * Blood pressures \> 130/85 mmHg Exclusion Criteria: * Triglycerides \> 500 mg/dL * Diabetes mellitus * CVD * Consumption of \> 30 g alcohol/day * Use of agents affecting lipid metabolism * APOE2/E2 genotype * Creatinemia (\> 120 umol/L) * Hypothyroidism * Abnormal liver and muscle enzymes

Locations (1)

University of Western Australia

Perth, Western Australia, Australia

Outcomes

Primary Outcomes

ApoB transport rate

Time frame: 5 weeks

Secondary Outcomes

ApoA and C-III transport rate

Time frame: 5 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.